Saturday 17 October 2026
Export SLXN’s income statement to Excel — free account
Silexion Therapeutics Corp
SLXN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 88.0%, free cash flow fell 16.6% and total debt fell 47.0%, each against the same quarter a year earlier.
0.15
0.04
−21.05%
Follow SLXN
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 1,440.00 | 1,449.00 | 1,515.00 | 31.05 | 16.50 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 1,527.00 | 1,518.00 | 1,749.75 | 2,033.70 | 517.50 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 3 | 0 | 0 | 0 | 14 | 14 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | 0 | (1) | 1 | (5) | (17) | (12) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | — | 0 | (1) | 1 | (5) | (17) | (12) | |||||
| Depreciation | — | — | — | — | 0 | — | — | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | (212.35) | (308.65) | 234.91 | (6,854.42) | (3,952.02) | (89.60) | |||||
| Cash flow | — | — | — | — | (83.33) | (586.33) | 326.56 | (6,470.00) | (1,999.05) | (81.35) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 94.29 | (5.24) | (0.07) | |||||
| Free cash flow | — | — | — | — | (83.33) | (586.33) | 326.56 | (6,375.71) | (2,004.29) | (81.41) | |||||
| Book value | — | — | — | — | (188.89) | (39.46) | (481.12) | 4,287.14 | (949.76) | 19.57 | |||||
| Shares, m | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (1) | 1 | (5) | (8) | (11) | ||||
| Capex | — | — | — | — | 0 | — | — | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | 0 | (1) | 1 | (4) | (8) | (11) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | 0 | (1) | 3 | (1) | 4 | ||||
| Total debt | — | — | — | — | — | — | 1 | — | 3 | 2 | |||||
| Net debt | — | — | — | — | 0 | 0 | 0 | (5) | 2 | (4) | |||||
| Shareholders’ equity | — | — | — | — | 0 | 0 | (1) | 3 | (4) | 3 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (189.18) | (1.31) | 0.50 | (8.10) | (405.05) | (236.40) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | (0.34) | 570.61 | (90.02) | 74.55 | 204.96 | 1,718.90 | |||||
Negative figures in brackets.
Charts ten years each
Silexion Therapeutics Corp vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MBIO Mustang Bio, Inc. | $2.9M | — (loss-making) | — | — | n/m | +27.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BCAB BioAtla, Inc. | $2.9M | — (loss-making) | — (loss-making) | +4,233.33% (above 0%: growing) | n/m | +97.03% (above 0%: growing) | 100.00% | 3.49% | Compare |
| ONCO Onconetix, Inc. | $2.9M | 0.0× | — (loss-making) | −83.94% (below 0%: shrinking) | n/m | −36.00% (below 0%: shrinking) | 25.15% | (15,969.59%) | Compare |
| VIVS VivoSim Labs, Inc. | $2.8M | — (loss-making) | — (loss-making) | −51.35% (below 0%: shrinking) | n/m | +17.87% (above 0%: growing) | 100.00% | (15,327.78%) | Compare |
| AFMDQ Affimed N.V. | $2.8M | — (loss-making) | — (loss-making) | −92.02% (below 0%: shrinking) | n/m | +46.95% (above 0%: growing) | 100.00% | (9,216.90%) | Compare |
| HCWB HCW Biologics Inc. | $2.8M | — (loss-making) | — (loss-making) | +1,954.55% (above 0%: growing) | n/m | −20.84% (below 0%: shrinking) | (69.25%) | (2,335.03%) | Compare |
| SLXN Silexion Therapeutics Corp | $2.7M | — (loss-making) | — | — | n/m | −16.63% (below 0%: shrinking) | — | 0.00% | |
| GOVX GeoVax Labs Inc. | $2.6M | — (loss-making) | — (loss-making) | +183.44% (above 0%: growing) | n/m | +15.81% (above 0%: growing) | 100.00% | 0.00% | Compare |
| XRTX XORTX Therapeutics Inc. | $2.6M | — (loss-making) | — | — | n/m | −318.40% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $2.8M | — | — | +66.05% | — | +16.84% | 62.58% | (1,167.51%) |
Silexion Therapeutics Corp (SLXN) key facts
- Silexion Therapeutics Corp (SLXN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, SLXN traded at $0.15, a market capitalization of $2.7 million.
- Return on equity was 1,718.9% and debt-to-equity 0.00.
Silexion Therapeutics Corp (SLXN) Latest News
No news at this impact. Lower the threshold for more.